Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
News about Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on its development of allogeneic T-cell immunotherapies and the regulatory and business milestones associated with its Epstein-Barr virus (EBV)-specific platform. Atara describes itself as a leader in T-cell immunotherapy, focused on off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with headquarters in Southern California. Much of the company’s recent news flow has highlighted progress and challenges around tabelecleucel (tab-cel or EBVALLO), its EBV-specific T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Investors following ATRA news can expect updates on FDA interactions, including Biologics License Application (BLA) submissions, Priority Review status, Prescription Drug User Fee Act (PDUFA) target action dates, and Complete Response Letters. Releases have detailed how Atara and its partner Pierre Fabre Laboratories addressed Good Manufacturing Practice (GMP) observations, transferred the tabelecleucel IND and BLA, and responded to evolving FDA positions on the adequacy of the pivotal ALLELE study for accelerated approval.
Company news also covers financial results and corporate restructuring, such as quarterly earnings releases, changes in research and development and general and administrative expenses, workforce reductions, lease amendments, and the impact of tabelecleucel-related milestone payments and commercialization revenue. In addition, Atara has issued updates on its strategic alternatives review, describing potential transactions it may consider to maximize shareholder value.
For readers tracking ATRA, this news stream provides insight into Atara’s clinical and regulatory trajectory, its partnership with Pierre Fabre Laboratories on tabelecleucel/EBVALLO, and the company’s evolving cost structure and strategic direction. Regularly reviewing these updates can help contextualize movements in ATRA stock and developments in the EBV-focused cell therapy space.
Atara Biotherapeutics (NASDAQ: ATRA) announced that the FDA has accepted and granted Priority Review for tabelecleucel's Biologics License Application (BLA). Tabelecleucel is a groundbreaking treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), with a PDUFA date set for January 10, 2026.
The therapy, developed in collaboration with Pierre Fabre Pharmaceuticals (PFP), would be the first FDA-approved treatment for EBV+ PTLD patients who have failed prior therapy. The BLA submission includes data from over 430 patients, including the pivotal ALLELE study. Tabelecleucel has already received marketing authorization in Europe (EBVALLO™), the UK, and Switzerland.
Atara Biotherapeutics (Nasdaq: ATRA) announced that the FDA has accepted its Biologics License Application (BLA) for tabelecleucel (tab-cel®) with Priority Review status. The treatment is designed for adult and pediatric patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received prior therapy.
The FDA has set a PDUFA target action date of January 10, 2026. The BLA submission is supported by data from over 430 patients, including the pivotal ALLELE study which showed a significant 48.8% Objective Response Rate. If approved, tab-cel would become the first FDA-approved therapy for this indication.
Pierre Fabre Pharmaceuticals has taken over the Investigational New Drug (IND) Application for tabelecleucel from Atara Biotherapeutics (NASDAQ: ATRA). This transfer follows Atara's July 11 resubmission of the Biologics License Application (BLA) to the FDA, addressing manufacturing facility observations from January 2025's Complete Response Letter.
Pierre Fabre now manages all global clinical trial activities for tabelecleucel, including the pivotal Phase 3 ALLELE study and another trial for EBV-associated diseases. The company assumed global manufacturing responsibilities on March 31, including commercial supply for European markets where the therapy is already approved as EBVALLO®.
Tabelecleucel is an allogeneic, off-the-shelf, EBV-specific T-cell immunotherapy designed to target EBV-infected cells, approved in Europe since December 2022 for treating EBV+ PTLD in patients who have received prior therapy.
Atara Biotherapeutics (Nasdaq: ATRA) has resubmitted its Biologics License Application (BLA) to the FDA for tabelecleucel (tab-cel®), targeting Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients who have received prior therapy. The resubmission addresses manufacturing facility observations from a January 2025 Complete Response Letter.
The BLA is supported by data from over 430 patients, including the pivotal ALLELE study showing a 48.8% Objective Response Rate. Upon FDA approval, Atara will receive a $40 million milestone payment from Pierre Fabre Laboratories, plus future double-digit tiered royalties on sales.
The company reports $22M in cash as of June 30, 2025, projecting runway into Q1 2026. Atara is transferring tab-cel operational activities to Pierre Fabre while maintaining BLA sponsorship.
CDR-Life has appointed Pascal Touchon, DVM, MBA to its Board of Directors. Touchon brings 40 years of international biopharmaceutical industry experience, particularly in oncology and strategic leadership. He currently serves as Chairman of Atara Biotherapeutics (NASDAQ: ATRA) and holds board positions at Ipsen, Medincell, and Catalym.
Previously, Touchon held key leadership roles at Novartis Oncology, including Global Head of Strategy and Business Development and Global Head of the Cell & Gene division, where he led the development and launch of the first FDA-approved cell and gene therapy in the US. His appointment aims to strengthen CDR-Life as it advances its M-gager® platform and pipeline of T cell engager therapeutics.
Atara Biotherapeutics (NASDAQ: ATRA), a T-cell immunotherapy company, has appointed two new members to its Board of Directors following the completion of their $16 million offering. James Huang, Founder and Managing Partner of Panacea Venture, brings 37 years of biotech experience, including leadership roles at Kleiner Perkins China, Vivo Ventures, and various pharmaceutical companies. Nachi Subramanian, currently Managing Director at Redmile Group, joins with extensive financial experience from his fourteen-year tenure at J.P. Morgan and background in Institutional Equities.
Atara Biotherapeutics (NASDAQ: ATRA) has announced the pricing of an underwritten registered direct offering to select institutional investors, including Adiumentum Capital Management, EcoR1 Capital, Panacea Venture, and Redmile Group. The offering consists of 834,237 common stock shares at $6.61 per share and 1,587,108 pre-funded warrants at $6.6099 per warrant with a $0.0001 exercise price.
The offering, expected to close around May 16, 2025, aims to raise $16 million in gross proceeds. The funds will be used to support the company's biologics license application (BLA) approval process for tab-cel and general corporate purposes. TD Cowen is serving as the sole bookrunner for this offering.
Atara Biotherapeutics (NASDAQ: ATRA) reported its Q4 and full year 2024 financial results, facing significant operational changes. The company received a Complete Response Letter (CRL) from FDA for EBVALLO in January 2025, leading to a clinical hold due to third-party manufacturing facility issues.
Key financial metrics include:
- Q4 2024 net loss of $12.7 million ($1.19 per share)
- Full year 2024 net loss of $85.4 million ($11.41 per share)
- Cash position of $42.5 million as of December 31, 2024
The company implemented a 50% workforce reduction and paused its CAR-T programs (ATA3219 and ATA3431) to preserve resources. Atara secured potential funding of up to $15 million through an equity line of credit with Redmile Group and is exploring strategic alternatives including potential merger or acquisition options.